Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Investor Presentation (October 2022)
15 slides from Imricor Medical Systems's investor presentation, Oct 27, 2022
Slide 1: Investor Presentation October 2022
For personal use only Investor Presentation October 2022 IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Disclaimer
Disclaimer For personal use only The material contained in this presentation is intended to be general background those which we expect, depending on the outcome of various factors. Investors and others information on Imricor Medical Systems, Inc. (Imricor) and its activities. are cautioned not to p
Slide 3: Appendix 4C Cashflow Results for Q3
For personal use only Appendix 4C Cashflow Results for Q3
Slide 4: Q3 Cashflow & Consumable Product Revenue
Q3 Cashflow & Consumable Product Revenue For personal use only • Net cash outflows from operating activities were US$4.7 million • Receipts from customers were US$246 thousand • Payments for operating costs were US$5.0 million* • Net cash outflows from investing activities were US$121 thousand • Net
Slide 5: Introduction to Imricor
For personal use only Introduction to Imricor
Slide 6: Transitioning cardiac ablation into a new kind of lab
Transitioning cardiac ablation into a new kind of lab Conventional x-ray EP lab iCMR EP lab (interventional cardiac magnetic resonance) For personal use only X-ray to iCMR Everyone else Only Imricor Physicians, Patients, Hospitals Imricor Annual consumable device revenue potential per iCMR • Same ki
Slide 7: Investment Highlights
Investment Highlights For personal use only Founder-led business with The world’s first and only deep med-tech experienced commercially available MRI management team compatible ablation catheter Large addressable market, Strong IP portfolio estimated to be $6bn1 in and patent protection What are the
Slide 8: Company timeline
Company timeline For personal use only 2019 Listed on ASX (ASX: IMR) 2020 Received CE mark approval for Vision-MR Ablation Cather & 2006 Imricor is established Vision-MR Dispersive Electrode 2007 Licensed IP from Johns 2015 Signed joint research Signed collaborative sales distribution agreement with
Slide 9: Path to significant scale
Path to significant scale For personal use only Growing with Expanding Addressing Today new Geographies Entire Market Indications iCMR Atrial Flutter iCMR Ventricular Tachycardia FDA approval in US Atrial Fibrillation Ablations (AFL) in the EU Ablations (VT) in the EU Ablations (Afib) worldwide • Ap
Slide 10: Taking control of our timeline and future
Taking control of our timeline and future Introducing Imricor’s NorthStar-MR 3D Mapping System1 • Prototype complete and For personal use only ready for deployment on Siemens systems • Planning to also apply NorthStar to other MRI platforms, such as GE Healthcare and Philips • Same 3D mapping system
Slide 11: Business Update and Outlook
For personal use only Business Update and Outlook
Slide 12: Key focus areas
Key focus areas For personal use only 1 2 3 Commercialisation VT Trial Funding • Activating sites • Trial approved in Europe • Exploring economic • Increasing procedure • Commence trial incentive programs volumes across active from regional • Ensure trial remains on government agencies sites time sc
Slide 13: Q3 Highlights
Q3 Highlights • For personal use only Submitted for approval to commence VT clinical study • VISABL-VT (Vision-MR Ablation of VT) • Completed development of initial NorthStar-MR 3D Mapping System prototype • Deploying at clinical sites in Q4 for feedback and iteration • Expect to utilize NorthStar-M
Slide 14: Well positioned for growth
Well positioned for growth For personal use only - Active across nine sites in Europe, with more sites becoming active in Q4 - Submitted for approval to commence a real-time iCMR-guided ventricular tachycardia (VT) clinical study - New sales strategy being implemented under European Sales Director,
Slide 15: Contact Information
Contact Information For personal use only Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Rest of World Media: Nick Twohy Director of Marketing, Imrico
Imricor Medical Systems — Investor Presentation (October 2022) on 6ix